Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.
Generative AI falls short in accurately identifying global health policies
Generative AI tools enhance data collection in health policy analysis but show notable inaccuracies, especially in African and Eastern Mediterranean regions.